The presentation will include an update on the following drugs: laquinimod, the company's oral MS drug for which it is in partnership with Teva Pharmaceutical Industries Ltd.; ANYARA, Active Biotech's novel concept for the treatment of lung cancer; and other key projects in clinical development, such as TASQ, for prostate cancer; 57-57, for Lupus (SLE); and RhuDex® (licensed to Avidex Ltd.) for rheumatoid arthritis.
The Active Biotech audio and slide presentation will be web cast live on November 8 at 3:30 p.m. (ET) / 21.30 (CET). A replay will be available approximately one hour following the presentation and archived on the company's web site. To access the live and replay presentations, visit the Active Biotech web site - www.activebiotech.com.
About Active Biotech
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA.
Contacts:
Active Biotech AB U.S. Investors
P.O. Box 724, SE-220 07 Kathy Price
Lund, Sweden The Global Consulting Group
Tel: +46 (0)46-19 20 00 Tel: +1-(646) 284-9430
Fax: +46 (0)46-19 20 50 Email: kprice@hfgcg.com
Email: cecilia.hofvander@activebiotech.com